Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC

NCT07559175 is registered in ClinicalTrials.gov with Aimmune Nestlé Health Science US R&D, LLC as lead sponsor.

NCT NCT07559175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07559175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC
Lead sponsor
Aimmune Nestlé Health Science US R&D, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
October 31, 2026
Completion date
September 30, 2027
Enrollment
66 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis (cf), exocrine pancreatic insufficiency (epi), pancreatic diseases, pancreatic enzyme abnormality